| Literature DB >> 35242853 |
Xiaona Xia1, Qingguo Ren1, Jiufa Cui2, Hao Dong3, Zhaodi Huang1, Qingjun Jiang1, Shuai Guan1, Chencui Huang3, Jihan Yin4, Jingxu Xu3, Kongming Liang3, Hao Wang3, Kai Han3, Xiangshui Meng1.
Abstract
BACKGROUND: Previous radiomics analyses of hematoma expansion have been based on the traditional definition, which only focused on changes in intraparenchymal volume. However, the ability of radiomics-related models to predict revised hematoma expansion (RHE) with the inclusion of intraventricular hemorrhage expansion remains unclear. To develop and validate a noncontrast computed tomography (NCCT)-based clinical- semantic-radiomics nomogram to identify supratentorial spontaneous intracerebral hemorrhage (sICH) patients with RHE on admission.Entities:
Keywords: Revised hematoma expansion (RHE); computed tomography; machine learning; radiomics; supratentorial intraparenchymal hematomas
Year: 2022 PMID: 35242853 PMCID: PMC8825556 DOI: 10.21037/atm-21-6158
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flowchart of patient enrollment and exclusion criteria.
Figure 2The workflow of the radiomics analysis of hematoma.
Clinical characteristics of the training set and test set
| Variable | Training set (n=299) | Test set (n=77) | |||||
|---|---|---|---|---|---|---|---|
| No RHE (n=215) | RHE (n=84) | P value | No RHE (n=53) | RHE (n=24) | P value | ||
| Age (years) | 58.479±12.931 | 62.048±13.812 | 0.036a | 63.679±12.643 | 56.750±14.411 | 0.036a | |
| Male (%) | 139 (64.7) | 50 (59.5) | 0.409c | 31 (58.5) | 16 (66.7) | 0.496c | |
| GCS | 13 (11, 15) | 10 (6.75, 13) | 0.001b | 13 (10, 14) | 12 (9, 12.25) | 0.041b | |
| Onset to follow-up CT, h | 4.000 | 2.500 | 0.001b | 4.000 | 1.650 | 0.001b | |
| Serum glucose, mmol/L | 6.670 | 6.750 | 0.088b | 6.480 | 7.460 | 0.192b | |
| Platelet count, 109/L | 216.000 | 217.500 | 0.787b | 201.000 | 229.500 | 0.031b | |
| INR | 1.060 | 1.030 | 0.179b | 1.065 | 1.045 | 0.218b | |
| APTT, s | 29.400 | 30.400 | 0.186b | 30.450 | 29.350 | 0.380b | |
| D-dimer, ug/mL | 0.330 | 0.510 | 0.005b | 0.470 | 0.375 | 0.667b | |
| Baseline ICH volume, mL, n (%) | 12.577 | 32.544 | 0.000b | 18.369 | 33.123 | 0.002b | |
| Prior cerebral hemorrhage, n (%), present | 24 (11.2) | 7 (8.3) | 0.471c | 7 (13.2) | 6 (25.0) | 0.342c | |
| Prior ischemic stroke, n (%), present | 25 (11.6) | 9 (10.7) | 0.823c | 8 (15.1) | 4 (16.7) | 1.000c | |
| Diabetes, n (%), present | 21 (9.8) | 7 (8.3) | 0.702c | 7 (13.2) | 5 (20.8) | 0.606c | |
| Hypertension, n (%), present | 156 (72.6) | 57 (67.9) | 0.420c | 40 (75.5) | 17 (70.8) | 0.667c | |
| Coronary artery disease, n (%), present | 20 (9.3) | 18 (21.4) | 0.005c | 9 (17.0) | 4 (16.7) | 1.000c | |
| Alcohol consumption, n (%), present | 55 (25.6) | 12 (14.3) | 0.101c | 14 (26.4) | 3 (12.5) | 0.297c | |
| Smoking, n (%), present | 47 (21.9) | 16 (19.0) | 0.757c | 14 (26.4) | 6 (25.0) | 0.783c | |
| Previous anticoagulant therapy, n (%), present | 13 (6.0) | 5 (6.0) | 0.278c | 2 (3.8) | 2 (8.3) | 0.779c | |
| Previous antiplatelet therapy, n (%), present | 24 (11.2) | 25 (29.8) | 0.000c | 11 (20.8) | 4 (16.7) | 0.913c | |
| Hematoma location, n (%), deep | 169 (78.6) | 60 (71.4) | 0.188c | 38 (71.7) | 16 (66.7) | 0.655c | |
| Black hole sign, n (%), present | 27 (12.6) | 23 (27.4) | 0.002c | 4 (7.5) | 5 (20.8) | 0.194c | |
| Blend sign, n (%), present | 47 (21.9) | 29 (34.5) | 0.024c | 21 (39.6) | 11 (45.8) | 0.609c | |
| Swirl sign, n (%), present | 69 (32.1) | 50 (59.5) | 0.000c | 16 (30.2) | 9 (39.1) | 0.446c | |
| Island sign, n (%), present | 80 (37.2) | 48 (57.1) | 0.002c | 20 (37.7) | 18 (75.0) | 0.002c | |
| Satellite sign, n (%), present | 51 (23.7) | 34 (40.5) | 0.004c | 17 (32.1) | 16 (66.7) | 0.004c | |
| Midline shift, n (%), present | 160 (74.4) | 36 (42.9) | 0.000c | 34 (64.2) | 17 (70.8) | 0.566c | |
| IVH, n (%), present | 45 (21.0) | 35 (41.7) | 0.000c | 37 (69.8) | 11 (45.8) | 0.044c | |
a, two sample t test; b, Wilcoxon test; c, Chi-square test. RHE, revised hematoma expansion; GCS, Glasgow Coma Scale; INR, international normalized ratio; APTT, activated partial thromboplastin time; IVH, intraventricular hemorrhage.
Predictive performances of 4 models for hematoma expansion
| Machine learning | Training | Test | Validation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACC | SEN | SPE | AUC | ACC | SEN | SPE | AUC | ACC | SEN | SPE | AUC | |||
| BS | 0.6622 | 0.7738 | 0.5708 | 0.7147 | 0.6486 | 0.7917 | 0.5370 | 0.6563 | 0.6374 | 0.7714 | 0.4921 | 0.6437 | ||
| CSM | 0.7391 | 0.8095 | 0.6652 | 0.8065 | 0.6892 | 0.8333 | 0.5849 | 0.7054 | 0.6703 | 0.8000 | 0.5323 | 0.6864 | ||
| RM | 0.8696 | 0.8810 | 0.8304 | 0.9158 | 0.7568 | 0.8750 | 0.6731 | 0.8124 | 0.7582 | 0.8286 | 0.6557 | 0.7843 | ||
| CSRM | 0.9130 | 0.8929 | 0.8879 | 0.9429 | 0.8243 | 0.8148 | 0.9167 | 0.8447 | 0.8132 | 0.8571 | 0.7333 | 0.8287 | ||
BS, BRAIN score; CSM, clinical-semantic model; RM, radiomics model; CSRM, clinical-semantic radiomics model.
Predictive performance of 5 models for RHE
| Model | Training | Test | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ACC | SEN | SPE | AUC | ACC | SEN | SPE | AUC | ||
| SVM | 0.8361 | 0.8452 | 0.7885 | 0.8545 | 0.7403 | 0.7500 | 0.6724 | 0.8012 | |
| RF | 0.7559 | 0.7381 | 0.6949 | 0.8084 | 0.7013 | 0.7083 | 0.6271 | 0.7300 | |
| GBDT | 0.7826 | 0.6905 | 0.7333 | 0.8204 | 0.6883 | 0.6667 | 0.6167 | 0.7240 | |
| LR | 0.8696 | 0.8810 | 0.8304 | 0.9158 | 0.7568 | 0.8750 | 0.6731 | 0.8124 | |
| NB | 0.7190 | 0.6429 | 0.6598 | 0.7328 | 0.6494 | 0.3333 | 0.6176 | 0.6349 | |
ACC, accuracy; SEN, sensitivity; SPE, specificity; AUC, area under the curve; SVM, support vector machine; RF, random forest; GBDT, gradient boosting decision tree; LR, logistic regression; NB, naïve Bayes.
Independent risk factors in the univariate analysis
| Variable | Univariate analysis | |
|---|---|---|
| Odds ratio (95% CI) | P value | |
| Rad score | 12.492 (5.741–28.685) | <0.001 |
| CT time from ICH onset, h | 0.346 (0.203–0.581) | <0.001 |
| Satellite sign, present | 2.614 (1.551–4.422) | <0.001 |
| Swirl sign, present | 2.388 (1.432–4.009) | <0.001 |
| D-dimer, ug/mL | 0.983 (0.899–1.042) | 0.0062 |
| Baseline midline shift, present | 3.398 (2.016–5.777) | <0.001 |
| Serum glucose, mmol/L | 1.049 (0.95–1.158) | 0.00328 |
| Baseline ICH volume, mL | 2.204 (1.626–3.025) | <0.001 |
ICH, intracerebral hemorrhage; CI, confidence interval.
Figure 3Nomogram and calibration curves of the clinical semantic-radiomics model (CSRM). (A) Nomogram of the CSRM. (B) Calibration curves of the CSRM in the test set. (C) Calibration curves of the CSRM in the training set. (D) Calibration curves of the CSRM in the validation set.
Figure 4receiver operating characteristic (ROC) curves of different models. (A) ROC curves of different models in the training set. (B) ROC curves of different models in the test set. (C) ROC curves of different models in the validation set.
Figure 5Decision curve analysis (DCA) of different models. (A) DCA of different models in the training set. (B) DCA of different models in the test set. (C) DCA of different models in the validation set.